Skip to content

Scott L Burrows, Chief Financial Officer at Spyre Therapeutics, sold SYRE on Sep 30, 2026

Data as of Oct 16

▼ SELL$1.6M17,500 shares at $89.89Scott L Burrows Chief Financial OfficerSYRE Spyre Therapeutics, Inc.
Watch SYRE
Traded
Sep 30, 2026
Disclosed
Oct 2, 2026
Filed
2 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Scott L Burrows, Chief Financial Officer at Spyre Therapeutics, sold SYRE on Sep 30, 2026TRADEDDISCLOSED
SYRESimilar stocks (XLV — its sector index fund), rebased to SYRE's price on the disclosure day
SYRE since disclosure
−14.3%
after the sale
Similar stocks (XLV) since disclosure
+6.3%
XLV — its sector index fund

Change in closing price from Oct 2, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLScott L Burrows Chief Financial OfficerSYRE Spyre Therapeutics, Inc.$21.4Kdisclosed Oct 2 · filed 1 day after the trade
  2. ▼ SELLScott L Burrows Chief Financial OfficerSYRE Spyre Therapeutics, Inc.$193Kdisclosed Oct 2 · filed 1 day after the trade
  3. ▼ SELLScott L Burrows Chief Financial OfficerSYRE Spyre Therapeutics, Inc.$53.4Kdisclosed Oct 2 · filed 1 day after the trade
  4. ▼ SELLScott L Burrows Chief Financial OfficerSYRE Spyre Therapeutics, Inc.$135Kdisclosed Oct 2 · filed 1 day after the trade
  5. ▼ SELLScott L Burrows Chief Financial OfficerSYRE Spyre Therapeutics, Inc.$285Kdisclosed Oct 2 · filed 1 day after the trade

See every trade on SYRE →